Next Article in Journal
Determinants of the Bovine Leukemia Virus Envelope Glycoproteins Involved in Infectivity, Replication and Pathogenesis
Next Article in Special Issue
Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1
Previous Article in Journal
Searching for Common Mammalian Retroviruses in Pediatric Idiopathic Diseases
Previous Article in Special Issue
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
Article Menu

Export Article

Open AccessReview
Viruses 2016, 8(3), 85; doi:10.3390/v8030085

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies

1
Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
2
Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Martine L.M. Lamfers and E. Antonio Chiocca
Received: 28 December 2015 / Revised: 9 March 2016 / Accepted: 9 March 2016 / Published: 22 March 2016
(This article belongs to the Special Issue Oncolytic Viruses)
View Full-Text   |   Download PDF [1015 KB, uploaded 22 March 2016]   |  

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed. View Full-Text
Keywords: cancer; hematopoietic cell transplant; allogeneic; allo-HSCT; GVHD; GVC; MYXV cancer; hematopoietic cell transplant; allogeneic; allo-HSCT; GVHD; GVC; MYXV
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Villa, N.Y.; Rahman, M.M.; McFadden, G.; Cogle, C.R. Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses 2016, 8, 85.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top